Source: European Medicines Agency (EU) Revision Year: 2009 Publisher: sanofi-aventis, 174 Avenue de France, F-75013, Paris, France
ACOMPLIA 20 mg film-coated tablets.
| Pharmaceutical Form |
|---|
|
Film-coated tablet. Biconvex, teardrop-shaped, white tablets debossed with “20” on one side. |
Each tablet contains 20 mg rimonabant.
Excipients: The tablets contain approx. 115 mg lactose.
For a full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Rimonabant |
Rimonabant is a selective cannabinoid-1 receptor (CB1) antagonist that inhibits the pharmacological effects of cannabinoid agonists in vitro and in vivo. The endocannabinoid system is a physiological system present in brain and peripheral tissues (including adipocytes) that affects energy balance, glucose and lipid metabolism and body weight, and in neurons of the mesolimbic system modulates the intake of highly palatable, sweet or fatty foods. |
| List of Excipients |
|---|
|
Tablet core: Maize starch Tablet coating: Lactose monohydrate Tablet polishing: Carnauba wax (E903) |
PVC-aluminium blister packs containing 14, 28, 30, 56, 84, 90 and 98 film-coated tablets.
70 × 1 film-coated tablets in PVC-aluminium perforated unit dose blister packs.
Opaque white HDPE bottles containing 28, 98 and 500 film-coated tablets.
Not all pack sizes may be marketed.
sanofi-aventis, 174 Avenue de France, F-75013, Paris, France
EU/1/06/344/001-011
19 June 2006
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
